Last update Jan. 17, 2022

Amrinone

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Amrinone is a phosphodiesterase type 3 inhibitor, similar to milrinone, with positive vasodilator and inotropic properties. Indicated in the treatment of heart failure. Intravenous administration. There are many side effects and increased mortality with oral use.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weigh and low protein binding) make it likely that it would pass into breast milk in amounts which could be significant.

Amrinone and milrinone have a slower elimination rate in newborns and young infants (Laitinen 2000, Ramamoorthy 1998) and a higher risk of potentially serious side effects.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Kearney 2018), especially during the neonatal period and in the event of prematurity.

If used during lactation: express and discard breast milk and wait to breastfeed 10 to 15 hours after administration.


See below the information of this related product:

  • Milrinone ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)

Alternatives

  • Digoxin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Dobutamine Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Norepinephrine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Theophylline ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Amrinone is also known as


Amrinone in other languages or writings:

Group

Amrinone belongs to this group or family:

Tradenames

Main tradenames from several countries containing Amrinone in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 187 daltons
Protein Binding 32 - 43 %
VD 0.5 - 1.2 l/Kg
pKa 11.01 -
3.6 (2.6 - 4.1) hours

References

  1. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)
  2. Laitinen P, Ahonen J, Olkkola KT, Peltola K, Rautiainen P, Räsänen J. Pharmacokinetics of amrinone in neonates and infants. J Cardiothorac Vasc Anesth. 2000 Aug;14(4):378-82. Abstract
  3. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  4. Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg. 1998 Feb;86(2):283-9. Abstract
  5. Levy JH, Bailey JM. Amrinone: pharmacokinetics and pharmacodynamics. J Cardiothorac Anesth. 1989 Dec;3(6 Suppl 2):10-4. Review. Abstract
  6. Edelson J, Stroshane R, Benziger DP, Cody R, Benotti J, Hood WB Jr, Chatterjee K, Luczkowec C, Krebs C, Schwartz R. Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation. 1986 Mar;73(3 Pt 2):III145-52. Abstract

Total visits

3,633

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM